D05.SI Stock Today: January 29 UltraGreen IPO Revives SGX Deal Flow
UltraGreen IPO Singapore is back in focus as the US$400 million December float, the biggest non‑REIT listing in eight years, stirs SGX deal flow. For investors in D05.SI, the link is direct: DBS was a joint bookrunner, and a sustained pipeline can lift fee income. The stock trades near S$59.79, up 0.88%, with volume above average. Rising medtech listing demand, paired with DBS underwriting strength, sets a constructive backdrop for Singapore’s primary market and bank earnings sensitivity to deals.
D05.SI gains as deal momentum returns
D05.SI prints S$59.79, up 0.52 on the day, between S$59.65 and S$60.00. It now sits above the 50‑day S$55.97 and 200‑day S$50.25 averages. The price has edged past the prior 52‑week high of S$59.57. YTD gain is 5.57%, with 1‑year up 36.15%. Volume of 5.07 million exceeds the 4.08 million average, signaling solid interest.
UltraGreen IPO Singapore totaled about US$400 million, and DBS served as joint bookrunner. The blockbuster listing, highlighted by The Straits Times as a wealth‑creating event for the founder’s family, supports confidence in Singapore deals source. DBS can benefit through advisory, underwriting, and trading revenues if issuance stays active.
UltraGreen IPO Singapore aligns with rising medtech listing demand. Its leading U.S. dye niche and profitability add quality to the cohort. That combination can nudge the SGX IPO pipeline forward, drawing more healthcare and specialty tech issuers. For DBS, steadier origination and syndication work would add higher‑margin fees, complementing net interest income as rates drift and credit costs normalise.
DBS fundamentals: valuation, growth, and risks
At S$59.79, DBS trades at 15.23x EPS of S$3.91 and 2.47x book. The dividend per share is S$2.85, implying a 4.79% yield, attractive for income portfolios. Return on equity is 16.57%, consistent with a premium bank. Meyka’s latest company rating is A‑ (Buy), with a Stock Grade of B+ and a BUY suggestion based on multi‑factor scoring.
FY2024 momentum looks healthy: revenue growth 10.85% and EPS growth 11.93%. Net profit margin sits at 37.37%, while return on capital employed is 6.73%. These figures back the case that fee upside from UltraGreen IPO Singapore and broader issuance can add to a strong base, especially if wealth management flows and treasury markets remain supportive.
Debt‑to‑equity is 1.11, typical for a bank, while the current ratio is low by design due to balance sheet structure. Key risks include a slower SGX IPO pipeline, global risk‑off episodes, and margin pressure as rates shift. Overbought signals could also spark pullbacks. Still, stable credit trends and diversified fees can cushion volatility if issuance pauses.
Flows, fees, and what to watch next
UltraGreen IPO Singapore shows investors will back profitable, specialist issuers. We look for more healthcare, energy transition, and consumer names to refresh the SGX IPO pipeline. The Straits Times coverage of the listing’s wealth impact supports broad awareness and interest source. For DBS underwriting, a steady calendar can lift syndication, advisory, and post‑listing liquidity revenues.
Momentum stays firm: RSI 66.91, MACD positive with a 0.14 histogram, and ADX 35.14 signals a strong trend. Price sits above the Bollinger upper band at S$58.24, hinting at near‑term consolidation. ATR of S$0.57 frames typical daily swings. Traders can watch the S$59.57 breakout level and the 50‑day S$55.97 as support zones.
Base case: gradual gains as issuance normalises and UltraGreen IPO Singapore encourages follow‑ons. Meyka projections point to S$61.22 in one month and S$68.00 in 12 months, with 3‑year S$92.90. Upside: pipeline accelerates, boosting fees and sentiment. Downside: deal delays and global volatility pull shares toward the quarterly model at S$56.79.
Final Thoughts
UltraGreen IPO Singapore is a clear signal that quality issuance can return to SGX. For DBS, that means better odds of fee growth across underwriting, advisory, and trading support. The stock trades near record levels with strong momentum, but short‑term signals suggest a pause is possible. Income remains appealing at a 4.79% yield and solid profitability. We would track deal calendars, medtech listing demand, and pricing outcomes on upcoming offerings. For entries, consider scaling on dips toward key moving averages while keeping an eye on volume and spreads. As always, size positions to risk and diversify across sectors.
FAQs
Why does UltraGreen IPO Singapore matter for DBS investors?
It signals live demand for profitable medtechs on SGX. DBS was a joint bookrunner, so more listings can lift fee income across underwriting, advisory, and trading support. A healthier pipeline often improves market depth and wealth flows, which also helps banks’ treasury and wealth units. It is a clean, cyclical tailwind to watch.
Is D05.SI attractive on valuation today?
DBS trades at 15.23x earnings and 2.47x book, with a 4.79% dividend yield. ROE is 16.57%, supporting a premium to peers. Near‑term momentum is strong, though technicals are near overbought. For long‑term buyers, scaling entries on pullbacks toward the 50‑day average can balance value and trend.
What could sustain the SGX IPO pipeline after UltraGreen?
More high‑quality issuers in healthcare, energy transition, and consumer tech could follow. Clear profitability, sensible pricing, and post‑listing liquidity matter. If deals price well and trade up, confidence builds, encouraging more supply. That cycle supports DBS underwriting, trading revenues, and broader market participation from funds and family offices.
What are the key risks to the DBS fee outlook?
A risk‑off backdrop, weaker earnings from new issuers, or delayed approvals can slow listings. If pricing windows close, underwriting and advisory fees ease. Macro shocks, higher credit costs, or rate swings can also pressure bank shares. Active risk management and diversified revenue lines can soften the impact.
Disclaimer:
The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.
